The combinational effect of E6/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells
- 6 June 2018
- journal article
- research article
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (sup2) , 727-736
Abstract
In the present research, we assumed that reducing the amounts of E6 and E7 oncoproteins by a specific siRNA sequence and recovering p53 and RB proteins, along with the recovery of the FOXO1 protein by applying anti-miR-182, would increase apoptosis and reduce proliferation rate in cancer cells. The HPV16-positive CaSki cervical cancer cell line was used. 48 hours after transfection of siRNA for targeting E6 and E7 oncoproteins and anti-miR-182, expression of its cellular targets p53, p21 and FOXO1 was assessed by real-time PCR, western blot analysis and immunocytofluorescence staining. In all treatments, apoptosis rate and viability were evaluated using Annexin-V-FITC apoptosis detection kits and MTT assays, respectively. Among the designed siRNAs, E6-1 and E7-2 proved the most effective in reducing E6 and E7 expressions by increasing the apoptotic rates to 12.4% and 16%, respectively, after 48 hours. Also, using anti-miR-182 increased apoptotic rate to 12.7% 48 hours after transfection of cervical cancer cells. The combinational use of either E6-1 or E7-2 siRNAs with anti-miR-182 resulted in a rise in apoptosis to 19.3% and 26%, respectively, higher than those obtained from the individual application of either without anti-miR-182. The simultaneous use of siRNA E6-1 and siRNA E7-2 with cisplatin increased sensitivity to cisplatin and reduced the viability of the cancer cells as compared to the use of cisplatin alone. The simultaneous use of cisplatin and anti-miR-182 had no considerable effect on viability or apoptosis rate compared to cisplatin alone.Keywords
Funding Information
- National Institute of Genetic Engineering and Biotechnology
This publication has 47 references indexed in Scilit:
- Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancersCancer Gene Therapy, 2010
- Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial CancerCancer Research, 2010
- Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer CellsJournal of Biological Chemistry, 2009
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell linesMolecular Carcinogenesis, 2008
- Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cellsOncogene, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005
- The functions of animal microRNAsNature, 2004
- Biological activities and molecular targets of the human papillomavirus E7 oncoproteinOncogene, 2001